2Q approvals

2Q approvals

2Q approvals
Selected second quarter product approvals. List does not include approvable letters for Nuvigil armodafinil to treat excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome and shift work sleep disorder from Cephalon (CEPH); Fentora fentanyl buccal tablet to manage breakthrough cancer pain from CEPH; and MoviPrep as a bowel-cleansing agent

Read the full 547 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE